Cargando…

256 S-649266, a Novel Siderophore Cephalosporin: Mechanisms of enhanced activity and beta-lactamase stability

Detalles Bibliográficos
Autores principales:	Tsuji, Masakatsu, Ito, Akinobu, Horiyama, Tsukasa, Fukuhara, Norio, Nakamura, Rio, Yamano, Yoshionori, Shimada, Jingoro, Ishii, Yoshikazu, Yamaguchi, Keizo, Tateda, Kazuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	IDWeek 2014 Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5782115/ http://dx.doi.org/10.1093/ofid/ofu052.122

Ejemplares similares

252 S-649266, a Novel Siderophore Cephalosporin: In vitro activity against Gram-negative bacteria
por: Tsuji, Masakatsu, et al.
Publicado: (2014)

1351. In vitro Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, Against Enterobacteriaceae With Defined Extended-Spectrum Β-Lactamases and Carbapenemases
por: Jacobs, Michael R, et al.
Publicado: (2018)

In Vivo Pharmacodynamic Study of Cefiderocol, a Novel Parenteral Siderophore Cephalosporin, in Murine Thigh and Lung Infection Models
por: Nakamura, Rio, et al.
Publicado: (2019)

Metabolism, Excretion, and Pharmacokinetics of [(14)C]‐Cefiderocol (S‐649266), a Siderophore Cephalosporin, in Healthy Subjects Following Intravenous Administration
por: Miyazaki, Shiro, et al.
Publicado: (2019)

Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa
por: Ito, Akinobu, et al.
Publicado: (2016)

Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects
por: Katsube, Takayuki, et al.
Publicado: (2019)

In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria
por: Ito, Akinobu, et al.
Publicado: (2017)

746 Tolerability of Cephalosporins and Carbapenems in Patients with Reported Penicillin Allergies in a Real World Setting
por: Hansen, Heather, et al.
Publicado: (2014)

423 Comparison of pediatric community-acquired, healthcare-associated, and hospital-acquired infections caused by extended-spectrum cephalosporin-resistant Enterobacteriaceae
por: Adler, Amanda, et al.
Publicado: (2014)

Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae
por: Ito, Akinobu, et al.
Publicado: (2019)

Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae
por: Ito, Akinobu, et al.
Publicado: (2018)

Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects
por: Saisho, Yutaka, et al.
Publicado: (2018)

488 Treatment Outcomes in Patients with Extended-Spectrum Beta-lactamase Producing Organisms
por: Lee, Eunbae, et al.
Publicado: (2014)

135 Fosfomycin Susceptibilities Among Uropathogenic Extended Spectrum Beta-Lactamase-producing Enterobacteriacea
por: Abbo, Lilian, et al.
Publicado: (2014)

694 Bone and joint infection due to bacteria producing Extended Broad Spectrum Beta lactamase
por: Rouzaud, Claire, et al.
Publicado: (2014)

716 Risk Factors for Resistance to Beta-lactam/Beta-lactamase Inhibitors and Carbapenems in Bacteroides spp. Bacteremia
por: Smith, Janessa, et al.
Publicado: (2014)

270 SYN-004, a Class A Beta-Lactamase Therapy for the Prevention of Antibiotic-Induced Disruption of Intestinal Microflora
por: Kaleko, Michael, et al.
Publicado: (2014)

717 Clinical characteristics and outcome of metallo-β-lactamase-producing Enterobacter cloacae bacteremia at a tertiary care cancer center in Japan
por: Sasaki, Shugo
Publicado: (2014)

343 Risk Factors for Extended-Spectrum Beta-Lactamase Infection and Evaluation of Carbapenem Use Patterns and Appropriateness in a County Hospital Setting
por: Su, Henry, et al.
Publicado: (2014)

In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe
por: Longshaw, Christopher, et al.
Publicado: (2020)

486 Meropenem and Piperacillin-tazobactam have Comparable Outcomes in Treatment of Bloodstream Infections Caused by Extended Spectrum Beta-lactamase Producing E.coli and Klebsiellae
por: Harris, Patrick, et al.
Publicado: (2014)

479 Clinical outcomes in patients with extended-spectrum-beta-lactamase-producing (ESBL) Enterobacteriaceae bloodstream infections (ESB) treated with carbapenems (CP) and non-carbapenems (NC)
por: Chin, Judy, et al.
Publicado: (2014)

257 In Vitro Activity of Meropenem/RPX7009, a Carbapenem/β-lactamase Inhibitor Combination Tested Against Contemporary Populations of Enterobacteriaceae and KPC-producing Strains
por: Castanheira, Mariana, et al.
Publicado: (2014)

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016
por: Hackel, Meredith A., et al.
Publicado: (2018)

1664 Case Series of Imported Enteric Fever in Japan: Clinical Characteristics, Antibiotics Susceptibility, and Relapse Risk Factors
por: Matono, Takashi, et al.
Publicado: (2014)

1297. In-Vitro Antibacterial Activities of Cefiderocol (S-649266) Alone and With the Addition of Beta-Lactamase Inhibitors Against Multidrug-resistant Acinetobacter baumannii
por: Abdul-Mutakabbir, Jacinda C, et al.
Publicado: (2020)

Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin
por: Katsube, Takayuki, et al.
Publicado: (2019)

679. In vitro Activity of Cefiderocol (CFDC), a Novel Siderophore Cephalosporin, Against Difficult-to-Treat-Resistant (DTR) Gram-Negative Bacterial Pathogens From the Multi-National Sentinel Surveillance Study, SIDERO-WT (2014–2017)
por: Longshaw, Christopher, et al.
Publicado: (2019)

304 Methicillin-resistant Staphylococcus aureus in Ohio EMS providers: A statewide cross-sectional study
por: Orellana, Robert, et al.
Publicado: (2014)

113 Procedure-specific Surgical Site Infection (SSI) Prevalence Widely Varies within Certain NHSN (National Healthcare Safety Network) Surgery Groups
por: Saeed, Mohammed, et al.
Publicado: (2014)

1124 Clinical characteristics of adult patients with influenza B and A infections during 2013/2014 flu season
por: Ahn, Mi Young, et al.
Publicado: (2014)

1543 Counting the Costs of Falsely Labeling Patients as HIV-Positive in Tahoua Region, Niger
por: Megill, Matthew
Publicado: (2014)

538 A Retrospective Study to Evaluate the Safety of Switching Antiretroviral Therapy (ART) to Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine (RPV/TDF/FTC) STR in Virologically Suppressed HIV-Infected Patients
por: Monczor, Ana, et al.
Publicado: (2014)

1067 Multi-Attribute Ranking Tool for Vaccines: Strategic Priority Setting to Support Vaccine Development
por: Madhavan, Guruprasad, et al.
Publicado: (2014)

1535 Knowledge, Practice, and Attitudes of University of California San Diego Medical Students with Regard to HIV and HIV Screening
por: Katsivas, Theodoros, et al.
Publicado: (2014)

1550 Can We Re-engage Patients with HIV Who Are Lost to Care? A Pilot Study in a Large Urban HIV Clinic
por: Lee, Dong Heun, et al.
Publicado: (2014)

473 Comparison of MicroScan System Prompt and Turbidity Methods for Measuring Vancomycin Minimum inhibitory concentration (MIC) against Methicillin-resistant Staphylococcus aureus (MRSA) with MIC of 2ug/ml, the Clinical Implications and economic impact of using alternative antimicrobial agents to vancomycin for MRSA with possible MIC of 2ug/ml
por: Kamran, Amir, et al.
Publicado: (2014)

870 The Epidemiology of CAUTI due to Candida spp. in the Intensive Care Unit (ICU) - Infection or Colonization?
por: Tashtoush, Nader, et al.
Publicado: (2014)

1454 Antifungal Susceptibility Patterns of a Global Collection of Fungal Isolates and Polysorbate-80 Effect on the Susceptibility of the Antifungal Classes
por: Castanheira, Mariana, et al.
Publicado: (2014)

766 Clinical Features and Outcome of Patients with Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) Infection
por: Alraddadi, Basem, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_561eo2fa46oiig3de9733idt56